Literature DB >> 20615205

The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain.

Andrew S Dixon1, Carol S Lim.   

Abstract

Protein interactions are critical for normal biological processes and molecular pathogenesis. While it is important to study these interactions, there are limited assays that are performed inside the cell, in the native cell environment, where the majority of protein-protein interactions take place. Here we present a method of studying protein interactions intracellularly using one protein of interest fused to a localization-controllable enhanced GFP (EGFP) construct and the other protein of interest fused to the red fluorescent protein, DsRed. Nuclear translocation of the EGFP construct is induced by addition of a ligand, and the difference in nuclear localization between the induced and noninduced states of the DsRed construct provides an indication of the interaction between the two proteins. This assay, the nuclear translocation assay (NTA), is introduced here as broadly applicable for studying protein interactions in the native environment inside cells and is demonstrated using forms of the coiled-coil domain from the breakpoint cluster region (Bcr) protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615205      PMCID: PMC2949290          DOI: 10.2144/000113452

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  28 in total

1.  Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin.

Authors:  A Miyawaki; J Llopis; R Heim; J M McCaffery; J A Adams; M Ikura; R Y Tsien
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

2.  Correlation among agonist dose, rate of import, and transcriptional activity of liganded progesterone receptor B isoform in living cells.

Authors:  Henan Li; Guang Yan; Steven E Kern; Carol S Lim
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

3.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

4.  Split ubiquitin as a sensor of protein interactions in vivo.

Authors:  N Johnsson; A Varshavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

Review 5.  The Philadelphia chromosome: a model of cancer and molecular cytogenetics.

Authors:  A A Sandberg; R M Gemmill; B K Hecht; F Hecht
Journal:  Cancer Genet Cytogenet       Date:  1986-03-15

6.  Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras.

Authors:  C S Lim; C T Baumann; H Htun; W Xian; M Irie; C L Smith; G L Hager
Journal:  Mol Endocrinol       Date:  1999-03

7.  Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera.

Authors:  H Htun; J Barsony; I Renyi; D L Gould; G L Hager
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.

Authors:  X Y Guo; J M Cuillerot; T Wang; Y Wu; R Arlinghaus; D Claxton; C Bachier; J Greenberger; I Colombowala; A B Deisseroth
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

9.  Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.

Authors:  Tim Beissert; Elena Puccetti; Andrea Bianchini; Saskia Güller; Simone Boehrer; Dieter Hoelzer; Oliver Gerhard Ottmann; Clara Nervi; Martin Ruthardt
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

10.  Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.

Authors:  H Tsukaguchi; H Matsubara; S Taketani; Y Mori; T Seido; M Inada
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  7 in total

Review 1.  Diversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system.

Authors:  Bram Stynen; Hélène Tournu; Jan Tavernier; Patrick Van Dijck
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Disruption of Bcr-Abl coiled coil oligomerization by design.

Authors:  Andrew S Dixon; Scott S Pendley; Benjamin J Bruno; David W Woessner; Adrian A Shimpi; Thomas E Cheatham; Carol S Lim
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

3.  Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.

Authors:  Andrew S Dixon; Jonathan E Constance; Tomoyuki Tanaka; Terence H Rabbitts; Carol S Lim
Journal:  Pharm Res       Date:  2011-12-20       Impact factor: 4.200

4.  Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Mol Pharm       Date:  2013-03-01       Impact factor: 4.939

5.  Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2012-08-07       Impact factor: 4.200

6.  Contribution of DEAF1 structural domains to the interaction with the breast cancer oncogene LMO4.

Authors:  Liza Cubeddu; Soumya Joseph; Derek J Richard; Jacqueline M Matthews
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

7.  Visualizing protein-protein interactions in plants by rapamycin-dependent delocalization.

Authors:  Joanna Winkler; Evelien Mylle; Andreas De Meyer; Benjamin Pavie; Julie Merchie; Peter Grones; Dani L Van Damme
Journal:  Plant Cell       Date:  2021-05-31       Impact factor: 11.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.